Q0234 Inj, tocilizumab-bavi, 1mgInjection, tocilizumab-bavi, for hospitalized adult patients with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation only, 1 mg
Q0234 payment limit: $6.327 per 1 MG, effective October 1, 2026 through December 31, 2026, based on 2Q26 ASP data. Coinsurance 20%. Paid at 95% of AWP (vaccine). Note: See COVID-19 vaccine pricing webpage for payment effective dates.
Status X: statutory exclusion, not paid under the PFS.
3 of 3 payer prior-auth lists that name Q0234 require prior authorization or set conditions: Cigna.
| Payer | Plan | State | Prior auth | Conditions | Since | Source |
|---|---|---|---|---|---|---|
| Cigna | ACA/IFP | All | prior auth required | Jul 1, 2026 | Master Precertification List (For Health Care Providers) | |
| Cigna | Basic Standard | All | prior auth required | Jul 1, 2026 | Master Precertification List (For Health Care Providers) | |
| Cigna | Complete/PHS+/Preferred | All | prior auth required | Jul 1, 2026 | Master Precertification List (For Health Care Providers) |
Q0234 appears in 1 coverage policy from Blue Cross & Blue Shield of Rhode Island.
| Payer | Policy | Role in policy | Reviewed | Document |
|---|---|---|---|---|
| Blue Cross & Blue Shield of Rhode Island | COVID-19 Monoclonal Antibody Treatment and Antiviral IV Medications Reimbursed | Reimbursed | listed, no stance | Jun 11, 2026 | payer document |
From payers' published prior-auth lists, coverage policies and state Medicaid fee schedules, updated Oct 16, 2026. The role is what the policy's own code table or text says about the code. Not a guarantee of coverage or payment; verify with the payer. CPT® is a registered trademark of the American Medical Association.